These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 24572810)

  • 1. Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.
    Shilo A; Ben Hur V; Denichenko P; Stein I; Pikarsky E; Rauch J; Kolch W; Zender L; Karni R
    RNA; 2014 Apr; 20(4):505-15. PubMed ID: 24572810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma.
    Cui H; Wu F; Sun Y; Fan G; Wang Q
    BMC Cancer; 2010 Jul; 10():356. PubMed ID: 20604928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway.
    Rauch J; Moran-Jones K; Albrecht V; Schwarzl T; Hunter K; Gires O; Kolch W
    Cancer Res; 2011 Jul; 71(13):4664-74. PubMed ID: 21512137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HnRNP A1/A2 and SF2/ASF regulate alternative splicing of interferon regulatory factor-3 and affect immunomodulatory functions in human non-small cell lung cancer cells.
    Guo R; Li Y; Ning J; Sun D; Lin L; Liu X
    PLoS One; 2013; 8(4):e62729. PubMed ID: 23658645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
    Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
    Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation.
    Shimoni-Sebag A; Lebenthal-Loinger I; Zender L; Karni R
    Carcinogenesis; 2013 Nov; 34(11):2498-504. PubMed ID: 23843040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aptamer BC15 against heterogeneous nuclear ribonucleoprotein A1 has potential value in diagnosis and therapy of hepatocarcinoma.
    Li S; Wang W; Ding H; Xu H; Zhao Q; Li J; Li H; Xia W; Su X; Chen Y; Fang T; Shao N; Zhang H
    Nucleic Acid Ther; 2012 Dec; 22(6):391-8. PubMed ID: 23062008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of hnRNP A2/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway.
    Shi X; Ran L; Liu Y; Zhong SH; Zhou PP; Liao MX; Fang W
    Oncol Rep; 2018 Mar; 39(3):939-950. PubMed ID: 29328485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous Nuclear Ribonucleoprotein A1 (hnRNP A1) and hnRNP A2 Inhibit Splicing to Human Papillomavirus 16 Splice Site SA409 through a UAG-Containing Sequence in the E7 Coding Region.
    Zheng Y; Jönsson J; Hao C; Shoja Chaghervand S; Cui X; Kajitani N; Gong L; Wu C; Schwartz S
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32759322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma.
    Golan-Gerstl R; Cohen M; Shilo A; Suh SS; Bakàcs A; Coppola L; Karni R
    Cancer Res; 2011 Jul; 71(13):4464-72. PubMed ID: 21586613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneous nuclear ribonucleoproteins A1 and A2 modulate expression of Tid1 isoforms and EGFR signaling in non-small cell lung cancer.
    Chen CY; Jan CI; Pi WC; Wang WL; Yang PC; Wang TH; Karni R; Wang TC
    Oncotarget; 2016 Mar; 7(13):16760-72. PubMed ID: 26919236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant-negative antagonists of the Ras-ERK pathway: DA-Raf and its related proteins generated by alternative splicing of Raf.
    Endo T
    Exp Cell Res; 2020 Feb; 387(2):111775. PubMed ID: 31843497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.
    Ghousein A; Mosca N; Cartier F; Charpentier J; Dupuy JW; Raymond AA; Bioulac-Sage P; Grosset CF
    Liver Int; 2020 Jan; 40(1):240-251. PubMed ID: 31612616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneous nuclear ribonucleoprotein A2/B1 in association with hTERT is a potential biomarker for hepatocellular carcinoma.
    Mizuno H; Honda M; Shirasaki T; Yamashita T; Yamashita T; Mizukoshi E; Kaneko S
    Liver Int; 2012 Aug; 32(7):1146-55. PubMed ID: 22372738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HnRNP A1 controls a splicing regulatory circuit promoting mesenchymal-to-epithelial transition.
    Bonomi S; di Matteo A; Buratti E; Cabianca DS; Baralle FE; Ghigna C; Biamonti G
    Nucleic Acids Res; 2013 Oct; 41(18):8665-79. PubMed ID: 23863836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation.
    Chan LH; Zhou L; Ng KY; Wong TL; Lee TK; Sharma R; Loong JH; Ching YP; Yuan YF; Xie D; Lo CM; Man K; Artegiani B; Clevers H; Yan HH; Leung SY; Richard S; Guan XY; Huen MSY; Ma S
    Cell Rep; 2018 Oct; 25(3):690-701.e8. PubMed ID: 30332648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways.
    Chen SL; Liu LL; Wang CH; Lu SX; Yang X; He YF; Zhang CZ; Yun JP
    Mol Oncol; 2020 Feb; 14(2):373-386. PubMed ID: 31670863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirtuin-mediated deacetylation of hnRNP A1 suppresses glycolysis and growth in hepatocellular carcinoma.
    Yang H; Zhu R; Zhao X; Liu L; Zhou Z; Zhao L; Liang B; Ma W; Zhao J; Liu J; Huang G
    Oncogene; 2019 Jun; 38(25):4915-4931. PubMed ID: 30858544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.